Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5986607 | 1.00 | TSHR (0.52) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Acetic Acid SCHEMBL11076307 | 0.88 | TSHR (0.58) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL987906 | 0.88 | TSHR (0.65) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL4367765 | 0.88 | TSHR (0.40) | TSHRTP53FFAR3LCKFYN | |
| Ethylene SCHEMBL687838 | 0.82 | TSHR (0.36) | TSHRTP53 | |
| SCHEMBL9747539 | 0.80 | TSHR (0.59) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL3814630 | 0.80 | TSHR (0.55) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL10403865 | 0.78 | TSHR (0.52) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL1460735 | 0.77 | TSHR (0.58) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL16198017 | 0.77 | TSHR (0.58) | TSHRCHRM2CHRM4CHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC (CA) | 2024-02-29 | — | — | US | disclosed |
| EP-3851447-B1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC (CA) | 2023-09-06 | — | — | EP | disclosed |
| US-20210386693-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2021-12-16 | — | — | US | disclosed |
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| EP-2862581-B1 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LP (CA) | 2021-08-11 | — | — | EP | disclosed |
| EP-3851447-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BHI Limited Partnership (CA) | 2021-07-21 | — | — | EP | disclosed |
| US-11020360-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BELLUS HEALTH INC. (CA) | 2021-06-01 | — | — | US | disclosed |
| US-10954250-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2021-03-23 | — | — | US | disclosed |
| US-10857109-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | Bellus Health, Inc. (CA) | 2020-12-08 | — | — | US | disclosed |
| US-20200253897-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2020-08-13 | — | — | US | disclosed |
| EP-2089417-B1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BHI LTD PARTNERSHIP (CA) | 2014-12-31 | — | — | EP | disclosed |
| US-20140220122-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BHI LIMITED PARTNERSHIP (CA) | 2014-08-07 | — | — | US | disclosed |
| US-8748656-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2014-06-10 | — | — | US | disclosed |
| WO-2013088255-A1 | PRODRUGS OF SECONDARY AMINE COMPOUNDS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-06-20 | — | — | WO | disclosed |
| WO-2010150840-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2010-12-29 | — | — | WO | disclosed |
| EP-2089417-A2 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS Health (International) Limited (CH) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009019534-A2 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080146642-A1 | Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease | BELLUS HEALTH INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-4914206-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0226896-A2 | Lankacidin derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | TSHR 4797/4885CHRM2 972/4885CHRM4 1155/4885 |
| US-11020360-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | TSHR 4814/4885CHRM2 940/4885CHRM4 1134/4885 |
| US-10857109-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | TSHR 4814/4885CHRM2 940/4885CHRM4 1134/4885 |
| US-20210386693-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | TSHR 4797/4885CHRM2 940/4885CHRM4 1136/4885 |
| US-20200253897-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | TSHR 4797/4885CHRM2 940/4885CHRM4 1136/4885 |
| US-10954250-B2 | Prodrugs of secondary amine compounds | HNMT, MAOB, UGT1A1 | TSHR 1367/4885CHRM2 314/4885CHRM4 1065/4885 |
| US-20080146642-A1 | Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease | DNPEP, DAO, APP | TSHR 2543/4885CHRM2 643/4885CHRM4 1131/4885 |
| US-20140220122-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | TSHR 4797/4885CHRM2 940/4885CHRM4 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.